Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights

April 25 (Reuters) – Biotech company Acuitas Therapeutics and Germany-based CureVac (5CV.DE), opens new tab have settled Acuitas’ lawsuit demanding credit for inventions related to COVID-19 vaccines, according to a filing on Thursday in Virginia federal court.
Acuitas sued CureVac last year in U.S. District Court for the Eastern District of Virginia, claiming its scientists should have been named as co-inventors of CureVac patents covering technology used in messenger RNA (mRNA)-based shots. CureVac told the court on Thursday, opens new tab that they had settled their dispute and will ask to dismiss the case.
Read More